- Previous Close
1,274.90 - Open
1,281.60 - Bid --
- Ask --
- Day's Range
1,274.90 - 1,328.65 - 52 Week Range
585.20 - 1,353.95 - Volume
435,635 - Avg. Volume
365,654 - Market Cap (intraday)
332.411B - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
137.02 - EPS (TTM)
9.53 - Earnings Date Feb 3, 2025 - Feb 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 9, 2022
- 1y Target Est
950.50
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
suvenpharm.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SUVENPHAR.NS
View MorePerformance Overview: SUVENPHAR.NS
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUVENPHAR.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUVENPHAR.NS
View MoreValuation Measures
Market Cap
331.91B
Enterprise Value
325.58B
Trailing P/E
136.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.17
Price/Book (mrq)
16.80
Enterprise Value/Revenue
34.43
Enterprise Value/EBITDA
84.14
Financial Highlights
Profitability and Income Statement
Profit Margin
25.73%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
9.34B
Net Income Avi to Common (ttm)
2.4B
Diluted EPS (ttm)
9.53
Balance Sheet and Cash Flow
Total Cash (mrq)
8.21B
Total Debt/Equity (mrq)
3.17%
Levered Free Cash Flow (ttm)
--